Episode Details
Back to Episodes
Daily Roundup | Curium Buys Lantheus for Up to $8B in Cash-and-CVR Deal
Published 1 month, 2 weeks ago
Description
Curium will pay up to $8.0 billion for Lantheus — Asubstantial cash payment per share plus additional contingent value rights tied to milestones stretching out several years. We break down theradiopharmaceutical consolidation across PYLARIFY, DEFINITY and Neuraceq, the Supernus–Indivior all-stock merger creating a $2.2 billion CNS company spanningADHD, epilepsy, Parkinson's and opioid use disorder, and Amgen's cloud breachthat stole patient data and intellectual property. Plus the open biotech IPO window and Moderna's seasonal flu vaccine decision Wednesday.
Visit us at thepharmacloseout.com.